Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

[1] Agricultural and Environmental Diagnostics Market Size (2028) (businessresearchinsights.com)

[2] Food Safety Testing Market Size Will Attain 35.6 Billion by (globenewswire.com)

[3] Infectious Disease Diagnostic Market Statistics | Forecast – 2030 (alliedmarketresearch.com)

Press Releases

Subscribe

Renowned horse race jockey and trainer conducts pilot test of LAMPlify®

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces that one of Sweden’s most accomplished horse race trainers, Madeleine Smith, has initiated a six-month pilot test of LAMPlify®.  The pilot test will focus on enhancing equine health and performance through early detection of potential respiratory viruses in horses. The test will be conducted via Madeleine Smith’s horse race training operation M. Smith Galopp.

Read more

Nomination Committee appointed for Diagonal Bio

Non-regulatory

Diagonal Bio today announces that the Nomination Committee has been appointed in preparation for the Annual General Meeting (AGM) on May 20, 2025.

Read more

Valberedning utsedd i Diagonal Bio AB (publ) inför årsstämman 2025

Non-regulatory

I enlighet med de principer för inrättande av valberedning som tidigare beslutats på årsstämman 2024, har följande valberedning utsetts för Diagonal Bio AB (publ.) inför årsstämman den 20 maj, 2025.

Read more

Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces a partnership with Kolgjini Stables (Stall Kolgjini), founded by renowned harness racer Lutfi Kolgjini, to conduct a three-month pilot test. Kolgjini Stables is a Swedish stable known for its expertise in growing horses for both breeding and for top-tier national and international competition. This pilot test starts immediately and aims to evaluate the potential of the LAMPlify® platform to provide rapid and accurate virus detection in horses.

Read more

Diagonal Bio announces that it is exploring financing options

Regulatory

Diagonal Bio AB (“Diagonal Bio” or “the Company”) today announces that the Board of Directors of the Company has engaged financial and legal advisors and decided to explore potential financing alternatives to secure the Company’s ongoing operations and support its strategic goals. The current funds last until mid-February 2025.

Read more

News

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Articles of association

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö